Compare CVS Health Corp (CVS) vs Zillow Group Inc Class A (ZG) Price & Performance

CVS Health trades at $87.12, down 0.94% on the day, with strong analyst support showing 85% buy ratings and a $111.20 consensus price target. The stock demonstrates solid revenue growth, reaching $402.07 billion in 2025, though net margins compressed to 1.18%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 forecast. Technical indicators show a bearish trend with key support at $85.

CVS presents a compelling value opportunity with attractive valuation ratios (P/E 23.17, P/S 0.27) and consistent dividend payments. However, declining profit margins and ongoing regulatory scrutiny pose risks. The company's Medicare expansion and healthcare services growth provide upside potential, but investors should monitor reimbursement pressures and competitive dynamics in the evolving healthcare landscape.

Zillow Group (ZG) trades at $30.00, up 7.26% over 24 hours, but remains in a technical downtrend with bearish moving average signals. The company reported a return to profitability in 2025 with net income of $23 million, though its P/E ratio of 130 is high. Recent earnings have shown volatility, with a miss in Q4 2025 but beats in subsequent quarters. Analyst sentiment is mixed, with a consensus 'Hold' rating and a price target of $48.87, suggesting significant potential upside from the current price.

The outlook for ZG hinges on execution in a challenging housing market. Opportunities include strong revenue growth and market leadership, but risks involve high valuation, affordability headwinds, and intense competition. The stock appears undervalued relative to analyst targets, but investors must weigh the premium valuation against macroeconomic pressures on the housing sector.